AcroMeta Group Limited (SGX: 43F) has announced a strategic partnership with Macro HRD SG Pte. Ltd. to venture into ambient temperature cellular logistics (ATCLS), a technology that could fundamentally transform the transportation of living cells and temperature-sensitive biological materials. The non-binding term sheet outlines AcroMeta's acquisition of a strategic stake in Macro-ATCLS Pte. Ltd., the commercial entity for this technology, and grants AcroMeta an option to exclusively license and deploy the platform across Southeast Asia.
Lawrence Toh, Executive Director of AcroMeta, said, "This proposed strategic partnership gives us the opportunity to build a position in an industry where cell and gene therapy logistics are expected to grow at double-digit rates in the years ahead. We see this as a natural extension of our strategy to grow our portfolio beyond our core operations, and we're excited about the potential to build a meaningful presence in bringing this technology into Southeast Asia."
ATCLS is an emerging technology licensed by Macro HRD, designed to eliminate reliance on conventional refrigerated and cryogenic cold chains. It uses proprietary ambient-temperature preservation and reactivation technologies, supported by its Gradient Equilibrium Decision Modeling (GEDM) platform for real-time governance, chain-of-identity and process control, enabling dormant living cells to be transported at ambient temperature and reactivated at the point of use.
The technology addresses rapidly expanding markets including stem cells, CAR-T/immune-cell therapy, gene therapy, regenerative medicine, organ and tissue transplantation, and cell-and-gene-therapy logistics. The underlying markets cited in the project materials range from US$5.2 billion for immune-cell therapy to US$47 billion for organ transplantation, while the global cell-and-gene-therapy 3PL market is estimated at US$1.81 billion in 2025 and projected to reach US$16.95 billion by 2035 (25.1% CAGR). Based on defined ambient-addressable segments, ATCLS estimates a Serviceable Addressable Market (SAM) of approximately US$14.5 billion by 2032, positioning the technology as a potential category-creating solution capable of reducing the cost, fragility and geographic limitations of conventional cold-chain logistics.
AcroMeta will have an option to acquire an exclusive licence to deploy the ATCLS technology across agreed territories in Southeast Asia, including the right to appoint sub-licensees. This structure allows AcroMeta to secure exclusive rights across the Southeast Asian markets, together with a first right to acquire additional territories, significantly expanding the Group's potential commercial reach for the ATCLS technology.
The Group intends to continue evaluating strategic opportunities to support its long-term value creation for shareholders. The Board remains focused on disciplined capital allocation as the Group progresses through its next phase of development.
